Amylin peptides

Garth Cooper; Willis Garth J. S.; C. Antony

Amylin peptides

Garth Cooper (Other), Willis Garth J. S. (Other), C. Antony (Other)

Research output: Patent

Abstract

A biologically active peptide associated with diabetes and designated herein "amylin" and processes for preparing it and assaying for it and for Type 2 diabetes are disclosed. The invention includes peptides having the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, substantially homologous sequences of amino acids, proamylin, as well as biologically active subfragments and conservative mutations. The peptide may be prepared from diabetic pancreata by solubilization of amyloid and isolation of the peptide by gel filtration and reverse phase chromotography. Amylin may also be synthesized, or it may be produced by recombinant DNA techniques using the disclosed nucleic acid sequences.

Original language	English
Patent number	5,367,052
Publication status	Published - 22 Nov 1994

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{ad8416d7e09a49159d7c3c83d043ca9e,

title = "Amylin peptides",

abstract = "A biologically active peptide associated with diabetes and designated herein {"}amylin{"} and processes for preparing it and assaying for it and for Type 2 diabetes are disclosed. The invention includes peptides having the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, substantially homologous sequences of amino acids, proamylin, as well as biologically active subfragments and conservative mutations. The peptide may be prepared from diabetic pancreata by solubilization of amyloid and isolation of the peptide by gel filtration and reverse phase chromotography. Amylin may also be synthesized, or it may be produced by recombinant DNA techniques using the disclosed nucleic acid sequences.",

author = "Garth Cooper and {Garth J. S.}, Willis and C. Antony",

note = "Issuing organisation: USPLocation issued: USA; 5,367,052",

year = "1994",

month = nov,

day = "22",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Amylin peptides

A2 - Cooper, Garth

A2 - Garth J. S., Willis

A2 - Antony, C.

N1 - Issuing organisation: USPLocation issued: USA

PY - 1994/11/22

Y1 - 1994/11/22

N2 - A biologically active peptide associated with diabetes and designated herein "amylin" and processes for preparing it and assaying for it and for Type 2 diabetes are disclosed. The invention includes peptides having the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, substantially homologous sequences of amino acids, proamylin, as well as biologically active subfragments and conservative mutations. The peptide may be prepared from diabetic pancreata by solubilization of amyloid and isolation of the peptide by gel filtration and reverse phase chromotography. Amylin may also be synthesized, or it may be produced by recombinant DNA techniques using the disclosed nucleic acid sequences.

AB - A biologically active peptide associated with diabetes and designated herein "amylin" and processes for preparing it and assaying for it and for Type 2 diabetes are disclosed. The invention includes peptides having the amino acid sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY, substantially homologous sequences of amino acids, proamylin, as well as biologically active subfragments and conservative mutations. The peptide may be prepared from diabetic pancreata by solubilization of amyloid and isolation of the peptide by gel filtration and reverse phase chromotography. Amylin may also be synthesized, or it may be produced by recombinant DNA techniques using the disclosed nucleic acid sequences.

M3 - Patent

M1 - 5,367,052

ER -

Amylin peptides

Abstract

UN SDGs

Fingerprint

Cite this